Disease Landscape and Forecast Insights

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by the accumulation of misfolded proteins in affected organs. Amyloid immunoglobulin light chain (AL), amyloid A (AA),…

Managing the frequency and severity of psychotic episodes is the primary goal in the treatment of schizophrenia. Atypical antipsychotics are the preferred drug class, driven by physicians’…

Ulcerative colitis (UC) is a chronic and progressive autoimmune disease that affects the gastrointestinal tract, specifically the colon and rectum. The principal goals of pharmacotherapy for UC are…

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in China. The treatment plan for NSCLC patients depends on their biomarker status; EGFR- and ALK-positive patients…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenia and the risk of progression to acute myeloid leukemia (AML). Bristol…

Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing…

Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in that country by 2033. Treatment of metastatic disease is dominated by…

The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…